May The Schwarz Be With You: UCB Proposes $5.6 Bil. Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Existing Schwarz deal with Pfizer unaffected by merger that would create a neurology heavyweight.
You may also be interested in...
Schwarz Pharma Settles False Claims Suit For $22 Million, As DoJ Continues Focus On DESI Drugs
Lawsuit alleges Schwarz failed to advise CMS that two products, including the nitroglycerin patch Deponit, did not qualify for federal reimbursement.
Schwarz Pharma Settles False Claims Suit For $22 Million, As DoJ Continues Focus On DESI Drugs
Lawsuit alleges Schwarz failed to advise CMS that two products, including the nitroglycerin patch Deponit, did not qualify for federal reimbursement.
Pfizer Toviaz Clears FDA For OAB: Three-Year Window To Establish Detrol Successor
Anti-muscarinic agent acquired from Schwarz in 2006 to hit U.S. market in 2009; in time to build sales before Pfizer’s Detrol goes off-patent in 2012.